X IBD’s unique rating measures price performance with a 1 (worst) to 99 (best) score. The rating shows how a stock’s price behavior over the last 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history reveals that the best stocks tend to have an 80 or higher RS Rating as they launch their biggest climbs.
Omeros has climbed more than 5% past a 17.29 entry in a second-stage consolidation, meaning it’s now out of a proper buy range. Look for the stock to create a new buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.
Top and bottom line growth moved higher last quarter. Earnings were up 73%, compared to 0% in the prior report. Revenue increased from 72% to 92%.
The company earns the No. 37 rank among its peers in the Medical-Biomed/Biotech industry group. Corcept Therapeutics (CORT), Emergent Biosolutions (EBS) and Hutchison China MediTech (HCM) are among the top 5 highly rated stocks within the group.